{"id":"bcma-car-t-cells","safety":{"commonSideEffects":[{"rate":"null","effect":"Cytokine release syndrome"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL4594496","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BCMA-targeting CAR-T cells are a type of immunotherapy that uses genetically modified T cells to recognize and kill cancer cells expressing BCMA.","oneSentence":"BCMA-targeting CAR-T cells","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:27.872Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06038474","phase":"PHASE2","title":"Descartes-08 for Patients With Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cartesian Therapeutics","startDate":"2024-02-12","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":6},{"nctId":"NCT06413498","phase":"PHASE3","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2024-08-23","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT07250269","phase":"PHASE1","title":"Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis","status":"RECRUITING","sponsor":"Gracell Biotechnologies (Shanghai) Co., Ltd.","startDate":"2025-10-29","conditions":"Relapsed/Refractory AL Amyloidosis","enrollment":9},{"nctId":"NCT07490951","phase":"NA","title":"Cluster of Differentiation 19 (CD19)/B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Genocury Biotech Co., Ltd.","startDate":"2026-03-22","conditions":"Autoimmune Diseases","enrollment":20},{"nctId":"NCT07489534","phase":"PHASE2","title":"Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-09-29","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT07081646","phase":"PHASE1, PHASE2","title":"A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-08-18","conditions":"Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis","enrollment":91},{"nctId":"NCT07200089","phase":"PHASE1","title":"Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-05-31","conditions":"Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":40},{"nctId":"NCT06068400","phase":"NA","title":"Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Guangzhou Bio-gene Technology Co., Ltd","startDate":"2023-09-21","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":1},{"nctId":"NCT07477912","phase":"PHASE1, PHASE2","title":"Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology","startDate":"2025-02-01","conditions":"Multiple Myeloma Refractory","enrollment":30},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT03455972","phase":"PHASE1, PHASE2","title":"Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2018-02-20","conditions":"Safety and Efficacy","enrollment":43},{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT04181827","phase":"PHASE3","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-12","conditions":"Multiple Myeloma","enrollment":419},{"nctId":"NCT04960579","phase":"PHASE1","title":"P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma","status":"RECRUITING","sponsor":"Poseida Therapeutics, Inc.","startDate":"2022-05-05","conditions":"Multiple Myeloma","enrollment":275},{"nctId":"NCT04923893","phase":"PHASE3","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-19","conditions":"Multiple Myeloma","enrollment":743},{"nctId":"NCT05767359","phase":"PHASE2","title":"CAR- PRISM (PRecision Intervention Smoldering Myeloma)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-04-19","conditions":"Multiple Myeloma, Smoldering Multiple Myeloma","enrollment":20},{"nctId":"NCT07391657","phase":"PHASE3","title":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-23","conditions":"Relapsed Refractory Multiple Myeloma","enrollment":508},{"nctId":"NCT07391605","phase":"PHASE2","title":"Descartes-08 in Autoantibody Myositis","status":"NOT_YET_RECRUITING","sponsor":"Cartesian Therapeutics","startDate":"2026-03-01","conditions":"Antisynthetase Syndrome","enrollment":60},{"nctId":"NCT07340853","phase":"PHASE1","title":"CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Thomas Martin, MD","startDate":"2026-02-28","conditions":"Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT07458659","phase":"EARLY_PHASE1","title":"Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Chulalongkorn University","startDate":"2026-06-01","conditions":"Relapsed/Refractory Multiple Myeloma (MM)","enrollment":3},{"nctId":"NCT07451236","phase":"PHASE1, PHASE2","title":"CD19-BCMA Dual Nanobody Based CAR-T Cells for Patients With DSA","status":"NOT_YET_RECRUITING","sponsor":"Chang Yingjun","startDate":"2026-03-18","conditions":"Transplantation Candidates With Hematological Diseases","enrollment":18},{"nctId":"NCT06548607","phase":"EARLY_PHASE1","title":"Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases","status":"RECRUITING","sponsor":"Nanjing Bioheng Biotech Co., Ltd.","startDate":"2024-09-14","conditions":"SLE (Systemic Lupus), Systemic Sclerosis, ANCA Associated Vasculitis","enrollment":20},{"nctId":"NCT05032820","phase":"PHASE2","title":"Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2022-01-05","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT07073547","phase":"PHASE1","title":"A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-31","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT03070327","phase":"PHASE1","title":"BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-02-27","conditions":"Multiple Myeloma","enrollment":20},{"nctId":"NCT06066346","phase":"PHASE2","title":"A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-09-27","conditions":"Multiple Myeloma","enrollment":17},{"nctId":"NCT03601078","phase":"PHASE2","title":"An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-12-13","conditions":"Multiple Myeloma","enrollment":312},{"nctId":"NCT06897930","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-21","conditions":"Lupus Erythematosus, Systemic","enrollment":150},{"nctId":"NCT06947473","phase":"PHASE1, PHASE2","title":"Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2026-03-18","conditions":"Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension","enrollment":45},{"nctId":"NCT06947460","phase":"PHASE1, PHASE2","title":"CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-04-18","conditions":"Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension","enrollment":45},{"nctId":"NCT07441525","phase":"EARLY_PHASE1","title":"UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-02-03","conditions":"Autoimmune Hemolytic Anemia, Primary Immune Thrombocytopenic Purpura, Evans Syndrome","enrollment":27},{"nctId":"NCT05870917","phase":"PHASE2","title":"A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-04-25","conditions":"Plasma Cell Leukemia","enrollment":20},{"nctId":"NCT07444307","phase":"PHASE1","title":"A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Hangzhou Qihan Biotech Co., Ltd.","startDate":"2025-12-15","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":18},{"nctId":"NCT07169500","phase":"PHASE1, PHASE2","title":"Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-03","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT07435779","phase":"EARLY_PHASE1","title":"Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study","status":"RECRUITING","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2026-02-04","conditions":"UC","enrollment":12},{"nctId":"NCT07416682","phase":"EARLY_PHASE1","title":"CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell Neoplasms","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2026-01-31","conditions":"High-risk Plasma Cell Neoplasms","enrollment":20},{"nctId":"NCT03602612","phase":"PHASE1","title":"T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-14","conditions":"Myeloma-Multiple, Myeloma, Plasma-Cell","enrollment":35},{"nctId":"NCT06235229","phase":"PHASE1, PHASE2","title":"A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Gracell Biotechnologies (Shanghai) Co., Ltd.","startDate":"2023-12-26","conditions":"Multiple Myeloma","enrollment":110},{"nctId":"NCT07246096","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2026-02-20","conditions":"Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Sclerosis","enrollment":60},{"nctId":"NCT06626919","phase":"PHASE1","title":"A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases","status":"RECRUITING","sponsor":"Arcellx, Inc.","startDate":"2025-04-30","conditions":"Muscular Diseases, Neuromuscular Manifestations, Autoimmune","enrollment":30},{"nctId":"NCT07429721","phase":"EARLY_PHASE1","title":"A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-03-01","conditions":"Multiple Myeloma (MM)","enrollment":24},{"nctId":"NCT07423572","phase":"EARLY_PHASE1","title":"Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhejiang Chinese Medical University","startDate":"2026-02-28","conditions":"Refractory Idiopathic Membranous Nephropathy","enrollment":18},{"nctId":"NCT05577000","phase":"PHASE1","title":"Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Martin, MD","startDate":"2021-10-18","conditions":"Refractory Multiple Myeloma, Relapsed Multiple Myeloma","enrollment":5},{"nctId":"NCT07421856","phase":"PHASE1, PHASE2","title":"Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.","status":"NOT_YET_RECRUITING","sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","startDate":"2026-02-01","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma Refractory","enrollment":24},{"nctId":"NCT06126341","phase":"","title":"A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-11-03","conditions":"Multiple Myeloma","enrollment":49},{"nctId":"NCT07416032","phase":"EARLY_PHASE1","title":"A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2026-02-20","conditions":"Immune Thrombocytopenia (ITP)","enrollment":27},{"nctId":"NCT07410377","phase":"EARLY_PHASE1","title":"UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2026-03","conditions":"Systemic Lupus Erythematosus, Inflammatory Myopathy","enrollment":15},{"nctId":"NCT07407010","phase":"PHASE1","title":"BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-06-01","conditions":"Relapsed Refractory Multiple Myeloma (RRMM)","enrollment":10},{"nctId":"NCT04322292","phase":"PHASE1","title":"A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2019-09-12","conditions":"Multiple Myeloma","enrollment":9},{"nctId":"NCT07295847","phase":"PHASE1","title":"A Study of AZD0120 in Autoimmune Diseases","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-09","conditions":"Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis","enrollment":27},{"nctId":"NCT07392528","phase":"EARLY_PHASE1","title":"Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Huanhu Hospital","startDate":"2026-03","conditions":"Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis, Myasthenia Gravis","enrollment":15},{"nctId":"NCT04155749","phase":"PHASE1","title":"Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2019-12-23","conditions":"Relapsed and Refractory Multiple Myeloma","enrollment":40},{"nctId":"NCT07234721","phase":"EARLY_PHASE1","title":"SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-01","conditions":"Relapsed and Refractory Multiple Myeloma (RRMM)","enrollment":9},{"nctId":"NCT05535244","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-10-17","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT07395479","phase":"EARLY_PHASE1","title":"A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-11-21","conditions":"Advanced Malignant Tumours","enrollment":50},{"nctId":"NCT06940297","phase":"PHASE2","title":"Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-06-23","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":44},{"nctId":"NCT07241468","phase":"EARLY_PHASE1","title":"An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-11-15","conditions":"Relapsed/Refractory Immune Nephropathy, Relapsed/Refractory Immune-mediated Kidney Disease","enrollment":36},{"nctId":"NCT07305116","phase":"PHASE1","title":"CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2025-12-01","conditions":"Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome","enrollment":15},{"nctId":"NCT06935474","phase":"PHASE1, PHASE2","title":"C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease","status":"NOT_YET_RECRUITING","sponsor":"AbelZeta Inc.","startDate":"2026-07","conditions":"Lupus Nephritis (LN)","enrollment":24},{"nctId":"NCT07318259","phase":"PHASE1","title":"Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","startDate":"2026-01-26","conditions":"Systemic Lupus Erythematosus","enrollment":18},{"nctId":"NCT06775912","phase":"EARLY_PHASE1","title":"Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases","status":"RECRUITING","sponsor":"Nanjing Bioheng Biotech Co., Ltd.","startDate":"2025-01-03","conditions":"SLE, Systemic Sclerosis, IIM","enrollment":18},{"nctId":"NCT07224373","phase":"PHASE1","title":"An Open-label Study of AZD0120 in Adults With Multiple Sclerosis","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-09","conditions":"Multiple Sclerosis","enrollment":24},{"nctId":"NCT07009899","phase":"PHASE2","title":"BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03-01","conditions":"Multiple Myeloma","enrollment":34},{"nctId":"NCT07377435","phase":"PHASE1","title":"DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM","status":"NOT_YET_RECRUITING","sponsor":"David Avigan","startDate":"2026-07","conditions":"Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma","enrollment":25},{"nctId":"NCT07376720","phase":"NA","title":"A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment","status":"NOT_YET_RECRUITING","sponsor":"Donghua Zhang","startDate":"2026-02-15","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT07369895","phase":"PHASE1","title":"Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"O&D BioTech Group CO., Limited","startDate":"2025-10-28","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":18},{"nctId":"NCT07350837","phase":"EARLY_PHASE1","title":"CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-31","conditions":"Highly Sensitized Patients Awaiting Kidney Transplant","enrollment":12},{"nctId":"NCT07359014","phase":"NA","title":"Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-11-01","conditions":"Relapse Multiple Myeloma","enrollment":25},{"nctId":"NCT07337785","phase":"EARLY_PHASE1","title":"CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases","status":"RECRUITING","sponsor":"Daishi Tian","startDate":"2025-12-12","conditions":"Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","enrollment":36},{"nctId":"NCT07361094","phase":"PHASE1","title":"Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Beijing Boren Hospital","startDate":"2025-11-06","conditions":"Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis, Relapsed/Refractory Idiopathic Inflammatory Myopathies","enrollment":12},{"nctId":"NCT06663046","phase":"EARLY_PHASE1","title":"Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma","status":"RECRUITING","sponsor":"Wondercel Biotech (ShenZhen)","startDate":"2025-07-01","conditions":"Multiple Myleoma, Refractory and Relapsed Multiple Myeloma","enrollment":30},{"nctId":"NCT07185490","phase":"EARLY_PHASE1","title":"IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-02-15","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Leukemia (PCL)","enrollment":40},{"nctId":"NCT07315087","phase":"PHASE1","title":"CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-01-01","conditions":"SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory Myopathies","enrollment":12},{"nctId":"NCT07341828","phase":"PHASE1","title":"A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy","status":"NOT_YET_RECRUITING","sponsor":"Huashan Hospital","startDate":"2026-02","conditions":"Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis","enrollment":15},{"nctId":"NCT07339540","phase":"EARLY_PHASE1","title":"the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-11-04","conditions":"Recurrent or Refractory Systemic Lupus Erythematosus, Recurrent or Refractory IgG4 Related Diseases, Recurrent or Refractory Systemic Sclerosis","enrollment":45},{"nctId":"NCT05172596","phase":"PHASE2","title":"PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-03-03","conditions":"Multiple Myeloma","enrollment":146},{"nctId":"NCT07333430","phase":"PHASE1","title":"Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Hadassah Medical Organization","startDate":"2026-01-15","conditions":"Relapsed/Refractory Multiple Myeloma (MM)","enrollment":60},{"nctId":"NCT07328581","phase":"PHASE1, PHASE2","title":"BCMA-CD19 cCAR T for the Treatment of Refractory Lupus","status":"NOT_YET_RECRUITING","sponsor":"iCell Gene Therapeutics","startDate":"2026-01","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":20},{"nctId":"NCT07324889","phase":"PHASE1, PHASE2","title":"An Open-label, Single-arm, Prospective, Multicenter, Phase I/II Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-T Cell Therapy for Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia","status":"NOT_YET_RECRUITING","sponsor":"Yihao Wang","startDate":"2026-01-31","conditions":"Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia","enrollment":24},{"nctId":"NCT07071909","phase":"PHASE1, PHASE2","title":"Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells","status":"WITHDRAWN","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-01-20","conditions":"Malignancy, Cancer, Hematological Malignancies","enrollment":""},{"nctId":"NCT07261345","phase":"EARLY_PHASE1","title":"Allogeneic Anti-CD19/BCMA CAR-T for Refractory Graves' Disease","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-19","conditions":"Graves' Disease","enrollment":4},{"nctId":"NCT07309744","phase":"EARLY_PHASE1","title":"Universal CAR-T Cell Injection Targeting CD19/BCMA in Patients With Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-12-20","conditions":"Moderate-to-severe Ulcerative Colitis, Crohn's Disease (CD)","enrollment":30},{"nctId":"NCT06530849","phase":"PHASE1","title":"A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Gracell Biotechnologies (Shanghai) Co., Ltd.","startDate":"2024-08-22","conditions":"Refractory Systemic Lupus Erythematosus","enrollment":18},{"nctId":"NCT05801939","phase":"PHASE2","title":"Cevostamab Following CAR T Cell Therapy for RRMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-07-11","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT07280793","phase":"EARLY_PHASE1","title":"CAR-T Cell Efficacy With Molecular Imaging in Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Xuzhou Medical University","startDate":"2025-12-17","conditions":"Non-invasive CAR-T Cell Monitoring, BCMA-targeted PET Imaging, CAR-T Cell Biodistribution and Persistence","enrollment":10},{"nctId":"NCT03758417","phase":"PHASE2","title":"A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Nanjing Legend Biotech Co.","startDate":"2019-01-23","conditions":"Multiple Myeloma","enrollment":123},{"nctId":"NCT06939166","phase":"EARLY_PHASE1","title":"Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases","status":"RECRUITING","sponsor":"Tianjin Huanhu Hospital","startDate":"2025-06-17","conditions":"Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Multiple Sclerosis","enrollment":12},{"nctId":"NCT06251076","phase":"PHASE4","title":"Plan Development for Giving Teclistamab in the Outpatient Setting","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-11-19","conditions":"Multiple Myeloma, Relapsed Cancer, Refractory Cancer","enrollment":15},{"nctId":"NCT07274059","phase":"EARLY_PHASE1","title":"Allogeneic UCB-derived CAR-T for SLE","status":"RECRUITING","sponsor":"Chengdu Ucello Biotechnology Co., Ltd.","startDate":"2025-03-26","conditions":"SLE - Systemic Lupus Erythematosus","enrollment":48},{"nctId":"NCT07266337","phase":"EARLY_PHASE1","title":"CD19/BCMA CAR-T for SLE","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Ucello Biotechnology Co., Ltd.","startDate":"2025-12-10","conditions":"SLE - Systemic Lupus Erythematosus","enrollment":24},{"nctId":"NCT07248176","phase":"NA","title":"Universal CAR-T Cell Therapy for MM","status":"RECRUITING","sponsor":"Bioray Laboratories","startDate":"2025-04-10","conditions":"Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":6},{"nctId":"NCT06519565","phase":"EARLY_PHASE1","title":"Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-08-20","conditions":"Immune Thrombocytopenia","enrollment":6},{"nctId":"NCT07003568","phase":"PHASE1","title":"Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-05-25","conditions":"Relapsed or Refractory Multiple Myeloma (RRMM)","enrollment":18},{"nctId":"NCT06056102","phase":"PHASE1","title":"CAR-T Cell Therapy for Desensitization in Kidney Transplantation","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-05-09","conditions":"Kidney Transplant, Kidney Failure, End Stage Renal Failure on Dialysis","enrollment":20},{"nctId":"NCT07003555","phase":"PHASE1","title":"Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration","status":"RECRUITING","sponsor":"Beijing GoBroad Hospital","startDate":"2025-05-25","conditions":"Relapsed or Refractory Multiple Myeloma (RRMM)","enrollment":18},{"nctId":"NCT07139509","phase":"PHASE1","title":"Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Xi'an No.3 Hospital","startDate":"2024-10-03","conditions":"Relapsed/Refractory Multiple Myeloma(MM)","enrollment":18},{"nctId":"NCT07249073","phase":"EARLY_PHASE1","title":"CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Multiple Myeloma","enrollment":9},{"nctId":"NCT06304636","phase":"PHASE1","title":"Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Cartesian Therapeutics","startDate":"2024-06-19","conditions":"Refractory Multiple Myeloma, Relapsed Multiple Myeloma","enrollment":4},{"nctId":"NCT04795882","phase":"PHASE1","title":"A New Study Evaluating the Activity of Modular CAR T for mYeloma","status":"RECRUITING","sponsor":"University College, London","startDate":"2022-04-22","conditions":"Multiple Myeloma","enrollment":27},{"nctId":"NCT07203404","phase":"EARLY_PHASE1","title":"A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.","status":"RECRUITING","sponsor":"Nanjing Bioheng Biotech Co., Ltd.","startDate":"2025-07-24","conditions":"SLE, LN, ANCA Associated Vasculitis","enrollment":84}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":138,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BCMA CAR-T cells injection"],"phase":"phase_2","status":"active","brandName":"BCMA CAR-T cells","genericName":"BCMA CAR-T cells","companyName":"Chongqing Precision Biotech Co., Ltd","companyId":"chongqing-precision-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"BCMA-targeting CAR-T cells Used for Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}